
Abbott Labs (ABT) Stock Forecast & Price Target
Abbott Labs (ABT) Analyst Ratings
Bulls say
Abbott Laboratories is favored because its near-term reset appears driven by temporary electrophysiology and diabetes headwinds rather than a break in the long-term growth thesis, while Nutrition, Diagnostics, and core device franchises continue to post resilient results. The company reported Nutrition revenue of about $2.3 billion in 3Q26, Diagnostics sales of roughly $1.6 billion, and EP growth of 10% in Rhythm Management and double-digit gains in ablation ex-LAA, underscoring broad-based operational strength. Management also expects the Nutrition separation by year-end 2027 to sharpen the portfolio and lift sales growth by 50-100 bps, gross margin by more than 200 bps, and operating margin by about 100 bps, while multiple product catalysts support 2027 acceleration.
Bears say
Abbott Laboratories is facing a negative outlook because its core businesses are exposed to persistent pricing pressure in Nutrition and Medical Devices, along with regulatory timing risk, competitive threats, and uncertainty around demand across emerging-market pharmaceutical launches. The company also faces share loss and slower growth in key franchises, as highlighted by competition in MitraClip, Libre, and Amulet versus entrenched rivals, while FX, inflation, supply-chain disruptions, and weaker-than-expected Covid-19 testing could further pressure results. Even with a 2026 revised forecast of $49.994B in revenue and $5.52 in adjusted EPS, the model still implies only mid-single-digit revenue growth and high-single-digit EPS growth, underscoring limited upside against these headwinds.
This aggregate rating is based on analysts' research of Abbott Labs and is not a guaranteed prediction by Public.com or investment advice.
Abbott Labs (ABT) Analyst Forecast & Price Prediction
Start investing in Abbott Labs (ABT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Abbott Labs (ABT) Forecast
Abbott Labs (ABT) Analyst Forecast & Price Prediction
Start investing in Abbott Labs (ABT)
Order type
Buy in
Order amount
Est. shares
0 shares